Steven Grunberg

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. doi request reprint Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
    Steven M Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, 89 Beaumont Avenue Given Bldg E214, Burlington, VT 05405, USA
    Support Care Cancer 17:589-94. 2009
  2. doi request reprint Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
    Steven Grunberg
    University of Vermont, 89 Beaumont Ave, Given Bldg E 214, Burlington, VT 05405, USA
    Support Care Cancer 18:S1-10. 2010
  3. ncbi request reprint Patient-centered management of chemotherapy-induced nausea and vomiting
    Steven Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Cancer Control 19:10-5. 2012
  4. ncbi request reprint Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont, Burlington, Vermont, USA
    Cancer Invest 23:392-8. 2005
  5. ncbi request reprint Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis
    S M Grunberg
    Department of Medicine, Hematology Oncology, University of Vermont, Burlington, VT, USA
    Ann Oncol 18:233-40. 2007
  6. ncbi request reprint Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, Burlington, Vermont, USA
    Cancer Invest 24:727-33. 2006
  7. doi request reprint Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-contr
    Steven M Grunberg
    University of Vermont, Burlington, VT 05405, USA
    Lancet Oncol 10:549-58. 2009
  8. ncbi request reprint Obstacles to the implementation of antiemetic guidelines
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    J Natl Compr Canc Netw 7:601-5. 2009
  9. doi request reprint Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA
    Support Care Cancer 19:S43-7. 2011
  10. doi request reprint Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE
    Steven Grunberg
    University of Vermont, Dept of Medicine, Fletcher Allen Health Care, 89 Beaumont Ave, Given Bldg E 214, Burlington, VT 05405, USA
    J Clin Oncol 29:1495-501. 2011

Detail Information

Publications32

  1. doi request reprint Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy
    Steven M Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, 89 Beaumont Avenue Given Bldg E214, Burlington, VT 05405, USA
    Support Care Cancer 17:589-94. 2009
    ..The present study evaluated a more convenient single-day three-drug antiemetic regimen for patients receiving moderately emetogenic chemotherapy...
  2. doi request reprint Chemotherapy-induced nausea and vomiting: contemporary approaches to optimal management. Proceedings from a symposium at the 2008 Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting
    Steven Grunberg
    University of Vermont, 89 Beaumont Ave, Given Bldg E 214, Burlington, VT 05405, USA
    Support Care Cancer 18:S1-10. 2010
    ..Chemotherapy-induced nausea and vomiting remains a significant problem for cancer patients...
  3. ncbi request reprint Patient-centered management of chemotherapy-induced nausea and vomiting
    Steven Grunberg
    Division of Hematology Oncology, Vermont Cancer Center, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Cancer Control 19:10-5. 2012
    ..Inadequate patient-provider communication is a significant barrier to optimal management of this debilitating toxicity...
  4. ncbi request reprint Phase I/II trial of paclitaxel and vinorelbine in advanced non-small cell lung cancer
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont, Burlington, Vermont, USA
    Cancer Invest 23:392-8. 2005
    ..The non-platin chemotherapy doublet of paclitaxel and vinorelbine given on this convenient 3-day schedule is worthy of further investigation in the treatment of non-small cell lung cancer...
  5. ncbi request reprint Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis
    S M Grunberg
    Department of Medicine, Hematology Oncology, University of Vermont, Burlington, VT, USA
    Ann Oncol 18:233-40. 2007
    ..Chemotherapy and radiotherapy remain the standards of treatment for many patients with cancer, but these modalities are often limited by distressing side-effects, most notably chemotherapy-induced nausea and vomiting (CINV)...
  6. ncbi request reprint Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, Burlington, Vermont, USA
    Cancer Invest 24:727-33. 2006
    ..Meningioma is a benign central nervous system tumor that is often progesterone-but not estrogen-receptor positive, making long-term antiprogestational therapy a logical treatment strategy...
  7. doi request reprint Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-contr
    Steven M Grunberg
    University of Vermont, Burlington, VT 05405, USA
    Lancet Oncol 10:549-58. 2009
    ....
  8. ncbi request reprint Obstacles to the implementation of antiemetic guidelines
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    J Natl Compr Canc Netw 7:601-5. 2009
    ..The relationship between these factors and the scientific basis of antiemetic guidelines must be considered to achieve optimal results and compliance...
  9. doi request reprint Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont College of Medicine, 89 Beaumont Avenue, Given Building E214, Burlington, VT 05405, USA
    Support Care Cancer 19:S43-7. 2011
    ..Additional efforts will be necessary to understand mechanisms of nausea and to identify optimal remedies...
  10. doi request reprint Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE
    Steven Grunberg
    University of Vermont, Dept of Medicine, Fletcher Allen Health Care, 89 Beaumont Ave, Given Bldg E 214, Burlington, VT 05405, USA
    J Clin Oncol 29:1495-501. 2011
    ..This study compared a 3-day oral aprepitant schedule to a regimen containing a single dose of the intravenous NK1RA fosaprepitant...
  11. ncbi request reprint Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment--how are we doing?
    Steven M Grunberg
    Fletcher Allen Health Care, UHC Campus St Joseph 3400, 1 South Prospect Street, Burlington, VT 05401, USA
    J Support Oncol 2:1-10, inside back cover; quiz 11. 2004
    ..In addition, new approaches to treatment, such as neurokinin-1 antagonists, acupressure, and acustimulation, will be discussed...
  12. ncbi request reprint Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update
    Steven M Grunberg
    University of Vermont, Burlington, Vermont 05401, USA
    Support Care Cancer 13:80-4. 2005
    ..A separate four-level classification system for emetogenicity of oral antineoplastic agents, which are often given over an extended period of time, is also proposed...
  13. ncbi request reprint Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis
    Steven M Grunberg
    Division of Hematology Oncology, University of Vermont, Burlington, Vermont 05401, USA
    Expert Opin Pharmacother 4:2297-303. 2003
    ..Palonosetron provides a convenience advantage if multiple-day 5-HT(3)-receptor antagonist therapy is anticipated and is a unique addition to the antiemetic armamentarium...
  14. ncbi request reprint Optimal use of antiemetics in the outpatient setting
    Steven M Grunberg
    University of Vermont, Burlington, USA
    Oncology (Williston Park) 16:1401-7; discussion 1407-8, 1412. 2002
    ..Investigation of additional potentially important neurotransmitter receptors, such as the opioid and cannabinoid receptors, may result in further improvements in antiemetic control and quality of life in coming years...
  15. ncbi request reprint Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score
    Steven M Grunberg
    Division of Hematology Oncology, Fletcher Allen Healthcare, University of Vermont, UHC Campus St Joseph 3400, 1 South Prospect Street, Burlington, VT 05401, USA
    Support Care Cancer 10:624-9. 2002
    ..46. This is a reasonable negative surrogate anchor and is being used in a current Cancer and Leukemia Group B (CALGB) study...
  16. ncbi request reprint New developments in the management of chemotherapy-induced emesis: do they impact on existing guidelines?
    Steven M Grunberg
    Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Oncology (Williston Park) 18:15-9. 2004
    ....
  17. ncbi request reprint Incidence of chemotherapy-induced nausea and emesis after modern antiemetics
    Steven M Grunberg
    Department of Medicine, University of Vermont, Burlington, Vermont 05401, USA
    Cancer 100:2261-8. 2004
    ..They also assessed whether physicians and nurses accurately recognized the incidence of acute and delayed CINV in their own practices...
  18. ncbi request reprint Paclitaxel and vinorelbine cause synergistic increases in apoptosis but not in microtubular disruption in human lung adenocarcinoma cells (A-549)
    Michael Jung
    Department of Pathology, University of Vermont College of Medicine, 89 Beaumont Avenue, Burlington, VT 05405, USA
    Histochem Cell Biol 121:115-21. 2004
    ....
  19. ncbi request reprint Aerorespiratory tract cancer in older patients
    Aqeel A Gillani
    Division of Hematology Oncology, The University of Vermont, UHC Campus, St Joseph 3400, 1 South Prospect Street, Burlington, VT 05401, USA
    Semin Oncol 31:220-33. 2004
    ..Although prevention remains the mainstay of management of aero-respiratory cancers, carefully planned treatment can result in therapeutic benefit with maintenance of quality of life...
  20. ncbi request reprint Malignant mesothelioma following thoracic radiotherapy for lung cancer
    Sabrina M Witherby
    Department of Medicine, University of Vermont College of Medicine, Vermont Cancer Center, 89 Beaumont Avenue, Given E 214, Burlington, VT 05405, USA
    Lung Cancer 57:410-3. 2007
    ..Secondary malignancies such as mesothelioma should be considered in patients who develop unexplained symptoms even long after treatment of a primary tumor...
  21. ncbi request reprint The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
    Paul J Hesketh
    Caritas St Elizabeth s Medical Center, Brighton, MA 02135 2997, USA
    J Clin Oncol 21:4112-9. 2003
    ....
  22. ncbi request reprint Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting
    Sant P Chawla
    Century City Hospital, Los Angeles, California 90067, USA
    Cancer 97:2290-300. 2003
    ..The current study sought to define the most appropriate dose regimen of oral aprepitant...
  23. doi request reprint First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Lecia V Sequist
    Massachusetts General Hospital Cancer Center, 32 Fruit St, Yawkey Suite 7B, Boston, MA 02114, USA
    J Clin Oncol 26:2442-9. 2008
    ..The multicenter iTARGET trial prospectively examined first-line gefitinib in advanced NSCLC patients harboring EGFR mutations and explored the significance of EGFR mutation subtypes and TKI resistance mechanisms...
  24. ncbi request reprint New directions in supportive care
    Steven M Grunberg
    Support Care Cancer 13:135-7. 2005
    ..Even symptoms such as fatigue and overall outlook may be defined in terms of appropriate enzymatic pathways. Evaluation and application of these advances in basic science are leading directly to new directions in supportive care...
  25. ncbi request reprint American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006
    Mark G Kris
    American Society of Clinical Oncology, Alexandria, VA, USA
    J Clin Oncol 24:2932-47. 2006
    ..The literature review focused on published randomized controlled trials, and systematic reviews and meta-analyses of published phase II and phase III randomized controlled trials...
  26. ncbi request reprint Management of patients receiving long-term treatment with mifepristone
    Irving M Spitz
    Institute of Hormone Research, Jerusalem, Israel
    Fertil Steril 84:1719-26. 2005
    ..To determine clinical side effects and biochemical and hematological abnormalities in patients with nonresectable meningioma on long-term mifepristone (RU 486) therapy...
  27. ncbi request reprint Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement
    Lawrence H Einhorn
    Division of Hematology Oncology, Indiana University School of Medicine, Indianapolis, IN 46202 5289, USA
    Support Care Cancer 13:112-6. 2005
    ..However, the results do not appear as successful as for highly emetic standard-dose chemotherapy...
  28. ncbi request reprint Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy
    Jørn Herrstedt
    Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark
    Cancer 104:1548-55. 2005
    ..An aprepitant (APR) regimen was evaluated for prevention of nausea and emesis due to moderately emetogenic chemotherapy (MEC) over multiple cycles...
  29. ncbi request reprint The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials
    David G Warr
    Princess Margaret Hospital, 610 University Avenue, Toronto, Ont, Canada M5G 2M9
    Eur J Cancer 41:1278-85. 2005
    ..In addition, even among patients who had emesis or needed rescue therapy, aprepitant was associated with a lower frequency of these events compared with the control regimen...
  30. ncbi request reprint Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    David G Warr
    Princess Margaret Hospital, Medical Oncology, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    J Clin Oncol 23:2822-30. 2005
    ..This is the first study in which the NK(1)-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy...
  31. ncbi request reprint Antiemetic guidelines: creating a more practical treatment approach
    Jim M Koeller
    University of Texas Health Science Center at San Antonio, Pharmacotherapy MSC 6220, 7703 Floyd Curl Drive, San Antonio, TX 78229 3900, USA
    Support Care Cancer 10:519-22. 2002
    ..Although this document alone may not solve all the challenges with appropriate antiemetic management, it will hopefully prove to be a step in the right direction...
  32. doi request reprint Birth and re-birth
    Steven M Grunberg
    Support Care Cancer 16:979. 2008